1
|
Liang S, Zheng YY, Pan Y. Blood transcriptome analysis uncovered COVID-19-myocarditis crosstalk. Microb Pathog 2024; 189:106587. [PMID: 38373644 DOI: 10.1016/j.micpath.2024.106587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 02/07/2024] [Accepted: 02/15/2024] [Indexed: 02/21/2024]
Abstract
BACKGROUND The condition of COVID-19-related myocarditis has emerged as a prominent contributor to COVID-19 mortality. As the epidemic persists, its incidence continues to rise. Despite ongoing efforts, the elucidation of COVID-19-related myocarditis underlying molecular mechanisms still requires further investigation. METHODS Hub genes for COVID-19-related myocarditis were screened by integrating gene expression profile analysis via differential expression in COVID-19 (GSE196822) and myocarditis (GSE148153 and GSE147517). After verification with independent datasets (GSE211979, GSE167028, GSE178491 and GSE215865), the hub genes were studied using a range of systems-biology approaches, such as ceRNA, TF-mRNA networks and PPI networks, as well as gene ontology, pathway enrichment, immune infiltration analysis and drug target identification. RESULTS TBKBP1 and ERGIC1 were identified as COVID-19-related myocarditis hub genes via integrated bioinformatics analysis. In addition, receiver operating characteristic curves constructed based on the expression levels of TBKBP1 and ERGIC1 could effectively distinguish healthy control individuals from patients with COVID-19. Functional enrichment analysis suggested several enriched biological pathways related to inflammation and immune response. Immune cell changes correlated with TBKBP1 and ERGIC1 levels in patients with COVID-19 or patients with COVID-19 and myocarditis. Tamibarotene, methotrexate and theophylline were identified as a potential drug targeting TBKBP1 and ERGIC1. CONCLUSION TBKBP1 and ERGIC1 were identified as crucial genes in the development of COVID-19-related myocarditis and have demonstrated a strong association with innate antiviral immunity. The present work may be helpful for further investigation of the molecular mechanisms and new therapeutic drug targets correlated with myocarditis in COVID-19.
Collapse
Affiliation(s)
- Shuang Liang
- Pharmacy Department, Hebei Medical University Third Hospital, Shijiazhuang, 050000, China.
| | - Ying-Ying Zheng
- Pharmacy Department, Hebei Medical University Third Hospital, Shijiazhuang, 050000, China
| | - Ying Pan
- Pharmacy Department, Hebei Medical University Third Hospital, Shijiazhuang, 050000, China
| |
Collapse
|
2
|
Marconi C, Lemmens L, Masclaux F, Mattioli F, Fluss J, Extermann P, Mendez P, Leuchter RHV, Stathaki E, Laurent S, Hammar E, Vannier A, Varvagiannis K, Guipponi M, Sloan-Bena F, Blouin JL, Abramowicz M, Fokstuen S. Bi-allelic loss of ERGIC1 causes relatively mild arthrogryposis. Clin Genet 2021; 100:329-333. [PMID: 34037256 PMCID: PMC8453841 DOI: 10.1111/cge.14004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/18/2021] [Accepted: 05/19/2021] [Indexed: 11/29/2022]
Abstract
Arthrogryposis describes the presence of multiple joint-contractures. Clinical severity of this phenotype is variable, and more than 400 causative genes have been proposed. Among these, ERGIC1 is a recently reported candidate encoding a putative transmembrane protein of the ER-Golgi interface. Two homozygous missense variants have been reported in patients with relatively mild non-syndromic arthrogryposis. In a consanguineous family with two affected siblings presenting congenital arthrogryposis and some facial dysmorphism we performed prenatal array-CGH, postnatal targeted exome and genome sequencing. Genome sequencing identified a homozygous 22.6 Kb deletion encompassing the promoter and first exon of ERGIC1. mRNA quantification showed the complete absence of ERGIC1 expression in the two affected siblings and a decrease in heterozygous parents. Our observations validate the pathogenic role of ERGIC1 in congenital arthrogryposis and demonstrate that complete loss of function causes a relatively mild phenotype. These findings will contribute to improve genetic counseling of ERGIC1 mutations.
Collapse
Affiliation(s)
- Caterina Marconi
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Laure Lemmens
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Frédéric Masclaux
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Francesca Mattioli
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Joël Fluss
- Pediatric Specialties division, Department of Women, Children and Adolescents, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | | | - Purificacion Mendez
- Obstetrics and Gynecology, Centre Médical Eaux-Vives, Genève (CH), Switzerland
| | - Russia Ha-Vinh Leuchter
- Pediatric Specialties division, Department of Women, Children and Adolescents, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Elissavet Stathaki
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Sacha Laurent
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Eva Hammar
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Anne Vannier
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Konstantinos Varvagiannis
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland
| | - Michel Guipponi
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland.,Department of Genetic Medicine and Development, School of Medicine, University of Geneva, Genève (CH), Switzerland
| | - Frédérique Sloan-Bena
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland.,Department of Genetic Medicine and Development, School of Medicine, University of Geneva, Genève (CH), Switzerland
| | - Jean-Louis Blouin
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland.,Department of Genetic Medicine and Development, School of Medicine, University of Geneva, Genève (CH), Switzerland
| | - Marc Abramowicz
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland.,Department of Genetic Medicine and Development, School of Medicine, University of Geneva, Genève (CH), Switzerland
| | - Siv Fokstuen
- Genetic Medicine division, Diagnostic Department, Hôpitaux Universitaires de Genève, Genève (CH), Switzerland.,Department of Genetic Medicine and Development, School of Medicine, University of Geneva, Genève (CH), Switzerland
| |
Collapse
|
3
|
Wang FR, Wei YC, Han ZJ, He WT, Guan XY, Chen H, Li YM. Aberrant DNA-PKcs and ERGIC1 expression may be involved in initiation of gastric cancer. World J Gastroenterol 2017; 23:6119-6127. [PMID: 28970727 PMCID: PMC5597503 DOI: 10.3748/wjg.v23.i33.6119] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Revised: 06/14/2017] [Accepted: 08/02/2017] [Indexed: 02/06/2023] Open
Abstract
AIM To investigate the molecular mechanisms of gastric carcinogenesis.
METHODS We used label-free quantification technology integrated with liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis to identify differentially expressed proteins in 160 specimens of normal gastric mucosa, gastric mucosa with mild dysplasia, moderate dysplasia, severe dysplasia, and early mucosal gastric cancer (GC) collected at the Second Hospital of Lanzhou University from 2010 to 2015. Immunohistochemistry was used to verify the differentially expressed proteins detected by LC-MS/MS.
RESULTS With a threshold of a 1.2-fold change and a P-value < 0.05 between mild dysplasia, moderate dysplasia, severe dysplasia or early mucosal GC and matched normal gastric mucosa tissues, proteomic analysis identified 365 significantly differentially expressed proteins. ERGIC1 expression decreased, while DNA-PKcs expression increased gradually along with different stages of GC initiation based on the tendency of fold change. The expression patterns of ERGIC1 and DNA-PKcs revealed by immunohistochemistry were consistent with the LC-MS/MS results.
CONCLUSION The results suggest that aberrant ERGIC1 and DNA-PKcs expression may be involved in GC initiation.
Collapse
Affiliation(s)
- Fu-Rong Wang
- School of Life Sciences, Lanzhou University, Lanzhou 730000, Gansu Province, China
- Department of Pathology, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Yu-Cai Wei
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Zhi-Jian Han
- The Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Wen-Ting He
- The Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Xiao-Ying Guan
- Department of Pathology, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Hao Chen
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Yu-Min Li
- School of Life Sciences, Lanzhou University, Lanzhou 730000, Gansu Province, China
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| |
Collapse
|
4
|
Reinstein E, Drasinover V, Lotan R, Gal-Tanamy M, Bolocan Nachman I, Eyal E, Jaber L, Magal N, Shohat M. Mutations in ERGIC1 cause Arthrogryposis multiplex congenita, neuropathic type. Clin Genet 2017; 93:160-163. [PMID: 28317099 DOI: 10.1111/cge.13018] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2017] [Revised: 03/13/2017] [Accepted: 03/15/2017] [Indexed: 11/29/2022]
Abstract
Arthrogryposis multiplex congenita (AMC) is heterogeneous group of disorders characterized by non-progressive joint contractures from birth that involve more than 1 part of the body. There are various etiologies for AMC including genetic and environmental depends on the specific type, however, for most types, the cause is not fully understood. We previously reported large Israeli Arab kindred consisting of 16 patients affected with AMC neuropathic type, and mapped the locus to a 5.5 cM interval on chromosome 5qter. Using whole exome sequencing, we have now identified homozygous pathogenic variant in the ERGIC1 gene within the previously defined linked region. ERGIC1 encodes a cycling membrane protein which has a possible role in transport between endoplasmic reticulum and Golgi. We further show that this mutation was absent in more than 200 samples of healthy unrelated individuals of the Israeli Arab population. Thus, our findings expand the spectrum of hereditary AMC and suggest that abnormalities in protein trafficking may underlie AMC-related disorders.
Collapse
Affiliation(s)
- E Reinstein
- Medical Genetics Institute, Meir Medical Center, Kfar-Saba, Israel.,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - V Drasinover
- Medical Genetics Institute, Rabin Medical Center, Petah Tikva, Israel
| | - R Lotan
- Medical Genetics Institute, Rabin Medical Center, Petah Tikva, Israel
| | - M Gal-Tanamy
- Medical Genetics Institute, Rabin Medical Center, Petah Tikva, Israel
| | - I Bolocan Nachman
- Medical Genetics Institute, Rabin Medical Center, Petah Tikva, Israel
| | - E Eyal
- Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Israel
| | - L Jaber
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Medical Genetics Institute, Rabin Medical Center, Petah Tikva, Israel
| | - N Magal
- Medical Genetics Institute, Rabin Medical Center, Petah Tikva, Israel
| | - M Shohat
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Medical Genetics institute, Maccabi HMO, Rechovot, Israel
| |
Collapse
|